Financial Data and Key Metrics Changes - Total revenues for Q1 2024 grew by 44% year-over-year to $81.9 million, compared to $56.9 million in Q1 2023 [13][24] - Adjusted EBITDA reached $26.4 million in Q1 2024, representing a 970% increase from $2.5 million in Q1 2023 [13][25] - GAAP net income improved to $17.8 million in Q1 2024, compared to a net loss of $6.8 million in Q1 2023 [14][25] - The company raised its financial guidance for 2024 and 2025, projecting revenues of over $355 million and $410 million, respectively [15][16] Business Line Data and Key Metrics Changes - Increased sales of immunoglobulin products contributed significantly to revenue growth, while external plasma sales decreased due to higher internal utilization for IVIG production [24] - Gross profit for Q1 2024 was $39.1 million, up from $16.5 million in the same period last year, resulting in a gross margin of approximately 48% [24][25] Market Data and Key Metrics Changes - The company is focusing on the immune deficient patient segment, particularly those with complex comorbidities, which is expected to drive future growth [17][18] - The demand for Asceniv is increasing, with the company reassessing its peak potential in the market [18] Company Strategy and Development Direction - The company is committed to enhancing immunoglobulin production yield through innovations in manufacturing processes, which are expected to contribute to revenue and earnings growth starting in the second half of next year [19] - ADMA is leveraging its strong balance sheet to pursue growth opportunities, including advancing preclinical R&D pipeline programs [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong demand for its products and a well-positioned balance sheet [14][19] - The company anticipates continued revenue growth and increased operating leverage, solidifying its position as a leading biopharma company [14][15] Other Important Information - The company is implementing a generative AI and machine learning platform to optimize production processes, which is expected to enhance operational efficiencies [20] - Management emphasized the importance of teamwork and dedication in achieving the company's milestones and growth [21][22] Q&A Session Summary Question: Current capacity utilization and peak potential - Management indicated that current capacity utilization is around 70% to 80%, with potential for expansion and yield enhancement not yet included in guidance [33][34] Question: Supply chain and donor strategies - Management confirmed that they are not leveraging RSV vaccines and are focusing on naturally occurring antibodies from high titer donors [38][39] Question: Reinvestment of capital and shareholder value - Management is considering various options for capital reinvestment, including paying down debt and enhancing shareholder value through potential stock buybacks [42][43] Question: Penetration of Asceniv and market dynamics - The majority of Asceniv utilization is in primary immune deficiency, with steady growth expected as the company continues to provide more product [66]

Adma Biologics (ADMA) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 60%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of 100%.Over the last four quarte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State o ...

Exhibit 99.1 ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA(1) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increase ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Adma Biologics (ADMA) .Adma Biologics currently has an average brokerage r ...

Core Viewpoint - Investors are expected to focus on the sales performance of ADMA Biologics' commercial products and pipeline updates during the first-quarter 2024 results announcement [1] Group 1: Sales Performance - ADMA Biologics markets plasma-derived biologics for immune deficiencies and infectious disease prevention, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [2] - Revenues in the last reported quarter increased approximately 48% year over year, driven by strong sales of immunoglobulin products, a trend likely to continue in the upcoming quarter [2] - The company's commercial specialty biologics portfolio has been experiencing exponential growth, which is expected to persist in the forthcoming quarter [2] Group 2: Regulatory Approvals - In March 2024, the FDA approved supplemental biologics license applications for Asceniv and Bivigam, extending room temperature storage conditions, which is anticipated to boost sales of these products in the first quarter of 2024 [3] Group 3: Revenue Guidance and Pipeline Development - Due to strong sales in 2023, ADMA Biologics raised its revenue guidance for 2024 and 2025, with investors looking for further updates during the upcoming earnings call [4] - The company plans to advance pre-clinical work for its S. pneumonia hyperimmune globulin pipeline program later in 2024, with management expected to provide updates during the conference call [4][5] Group 4: Earnings Surprise History - ADMA Biologics has a positive earnings surprise history, beating estimates in three of the last four quarters, with an average earnings surprise of 85% [6] - In the last reported quarter, the company achieved a 100% earnings surprise [6] Group 5: Earnings Predictions - Current analysis does not predict a definitive earnings beat for ADMA Biologics, as the Earnings ESP is 0.00% with both the Most Accurate Estimate and Zacks Consensus Estimate at 5 cents per share [7] - The company holds a Zacks Rank of 1 (Strong Buy) [7]

tazytaz/E+ via Getty Images Today, we are going to do something different to close out another trading week. In this column, I highlight three biotech stocks with favorable risk/reward profiles and that are trading for under ten bucks a share. Let's start with ADMA Biologics, Inc. (ADMA). This company is focused on manufacturing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. ADMA Biologics recently brought online the last of 10 large plasma collection fa ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

Adma Biologics (ADMA) ended the recent trading session at $6.27, demonstrating a +1.13% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.88%. On the other hand, the Dow registered a gain of 0.56%, and the technology-centric Nasdaq decreased by 2.05%.The the stock of infectious disease drug developer has risen by 0.16% in the past month, leading the Medical sector's loss of 6.4% and the S&P 500's loss of 2.57%.The upcoming earnings release of Ad ...

In the latest trading session, Adma Biologics (ADMA) closed at $6.04, marking a -1.95% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.58%. On the other hand, the Dow registered a loss of 0.12%, and the technology-centric Nasdaq decreased by 1.15%.Prior to today's trading, shares of the infectious disease drug developer had lost 0.48% over the past month. This has was narrower than the Medical sector's loss of 6.07% and the S&P 500's loss of 1.09% in that time.The ...